000135967 001__ 135967
000135967 005__ 20240229111723.0
000135967 0247_ $$2pmid$$apmid:88564
000135967 0247_ $$2ISSN$$a0099-5355
000135967 0247_ $$2ISSN$$a0140-6736
000135967 0247_ $$2ISSN$$a1474-547X
000135967 037__ $$aDKFZ-2018-00704
000135967 041__ $$aeng
000135967 082__ $$a610
000135967 1001_ $$aRicci, Cristian$$b0
000135967 245__ $$aAlcohol intake in relation to non-fatal and fatal coronary heart disease and stroke: EPIC-CVD case-cohort study.
000135967 260__ $$aLondon$$bBritish Medical Association56099$$c2018
000135967 3367_ $$2DRIVER$$aarticle
000135967 3367_ $$2DataCite$$aOutput Types/Journal article
000135967 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1550485311_679
000135967 3367_ $$2BibTeX$$aARTICLE
000135967 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000135967 3367_ $$00$$2EndNote$$aJournal Article
000135967 520__ $$aTo investigate the association between alcohol consumption (at baseline and over lifetime) and non-fatal and fatal coronary heart disease (CHD) and stroke.Multicentre case-cohort study.A study of cardiovascular disease (CVD) determinants within the European Prospective Investigation into Cancer and nutrition cohort (EPIC-CVD) from eight European countries.32 549 participants without baseline CVD, comprised of incident CVD cases and a subcohort for comparison.Non-fatal and fatal CHD and stroke (including ischaemic and haemorrhagic stroke).There were 9307 non-fatal CHD events, 1699 fatal CHD, 5855 non-fatal stroke, and 733 fatal stroke. Baseline alcohol intake was inversely associated with non-fatal CHD, with a hazard ratio of 0.94 (95% confidence interval 0.92 to 0.96) per 12 g/day higher intake. There was a J shaped association between baseline alcohol intake and risk of fatal CHD. The hazard ratios were 0.83 (0.70 to 0.98), 0.65 (0.53 to 0.81), and 0.82 (0.65 to 1.03) for categories 5.0-14.9 g/day, 15.0-29.9 g/day, and 30.0-59.9 g/day of total alcohol intake, respectively, compared with 0.1-4.9 g/day. In contrast, hazard ratios for non-fatal and fatal stroke risk were 1.04 (1.02 to 1.07), and 1.05 (0.98 to 1.13) per 12 g/day increase in baseline alcohol intake, respectively, including broadly similar findings for ischaemic and haemorrhagic stroke. Associations with cardiovascular outcomes were broadly similar with average lifetime alcohol consumption as for baseline alcohol intake, and across the eight countries studied. There was no strong evidence for interactions of alcohol consumption with smoking status on the risk of CVD events.Alcohol intake was inversely associated with non-fatal CHD risk but positively associated with the risk of different stroke subtypes. This highlights the opposing associations of alcohol intake with different CVD types and strengthens the evidence for policies to reduce alcohol consumption.
000135967 536__ $$0G:(DE-HGF)POF3-323$$a323 - Metabolic Dysfunction as Risk Factor (POF3-323)$$cPOF3-323$$fPOF III$$x0
000135967 588__ $$aDataset connected to PubMed,
000135967 650_7 $$08W8T17847W$$2NLM Chemicals$$aUrea
000135967 7001_ $$aWood, Angela$$b1
000135967 7001_ $$aMuller, David$$b2
000135967 7001_ $$aGunter, Marc J$$b3
000135967 7001_ $$aAgudo, Antonio$$b4
000135967 7001_ $$aBoeing, Heiner$$b5
000135967 7001_ $$avan der Schouw, Yvonne T$$b6
000135967 7001_ $$aWarnakula, Samantha$$b7
000135967 7001_ $$aSaieva, Calogero$$b8
000135967 7001_ $$aSpijkerman, Annemieke$$b9
000135967 7001_ $$aSluijs, Ivonne$$b10
000135967 7001_ $$aTjønneland, Anne$$b11
000135967 7001_ $$aKyrø, Cecilie$$b12
000135967 7001_ $$aWeiderpass, Elisabete$$b13
000135967 7001_ $$0P:(DE-He78)0907a10ba1dc8f53f04907f54f6fdcfe$$aKühn, Tilman$$b14$$udkfz
000135967 7001_ $$0P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a$$aKaaks, Rudolf$$b15$$udkfz
000135967 7001_ $$aSánchez, Maria-Jose$$b16
000135967 7001_ $$aPanico, Salvatore$$b17
000135967 7001_ $$aAgnoli, Claudia$$b18
000135967 7001_ $$aPalli, Domenico$$b19
000135967 7001_ $$aTumino, Rosario$$b20
000135967 7001_ $$aEngström, Gunnar$$b21
000135967 7001_ $$aMelander, Olle$$b22
000135967 7001_ $$aBonnet, Fabrice$$b23
000135967 7001_ $$aBoer, Jolanda M A$$b24
000135967 7001_ $$aKey, Timothy J$$b25
000135967 7001_ $$aTravis, Ruth C$$b26
000135967 7001_ $$aOvervad, Kim$$b27
000135967 7001_ $$aVerschuren, W M Monique$$b28
000135967 7001_ $$aQuirós, J Ramón$$b29
000135967 7001_ $$aTrichopoulou, Antonia$$b30
000135967 7001_ $$aPapatesta, Eleni-Maria$$b31
000135967 7001_ $$aPeppa, Eleni$$b32
000135967 7001_ $$aIribas, Conchi Moreno$$b33
000135967 7001_ $$aGavrila, Diana$$b34
000135967 7001_ $$aForslund, Ann-Sofie$$b35
000135967 7001_ $$aJansson, Jan-Håkan$$b36
000135967 7001_ $$aMatullo, Giuseppe$$b37
000135967 7001_ $$aArriola, Larraitz$$b38
000135967 7001_ $$aFreisling, Heinz$$b39
000135967 7001_ $$aLassale, Camille$$b40
000135967 7001_ $$aTzoulaki, Ioanna$$b41
000135967 7001_ $$aSharp, Stephen J$$b42
000135967 7001_ $$aForouhi, Nita G$$b43
000135967 7001_ $$aLangenberg, Claudia$$b44
000135967 7001_ $$aSaracci, Rodolfo$$b45
000135967 7001_ $$aSweeting, Michael$$b46
000135967 7001_ $$aBrennan, Paul$$b47
000135967 7001_ $$aButterworth, Adam S$$b48
000135967 7001_ $$aRiboli, Elio$$b49
000135967 7001_ $$aWareham, Nick J$$b50
000135967 7001_ $$aDanesh, John$$b51
000135967 7001_ $$aFerrari, Pietro$$b52
000135967 773__ $$0PERI:(DE-600)1476593-7$$gVol. 2, no. 8134$$pk934$$tThe @BMJ$$v361$$x0140-6736$$y2018
000135967 909CO $$ooai:inrepo02.dkfz.de:135967$$pVDB
000135967 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)0907a10ba1dc8f53f04907f54f6fdcfe$$aDeutsches Krebsforschungszentrum$$b14$$kDKFZ
000135967 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a$$aDeutsches Krebsforschungszentrum$$b15$$kDKFZ
000135967 9131_ $$0G:(DE-HGF)POF3-323$$1G:(DE-HGF)POF3-320$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lHerz-Kreislauf-Stoffwechselerkrankungen$$vMetabolic Dysfunction as Risk Factor$$x0
000135967 9141_ $$y2018
000135967 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000135967 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000135967 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000135967 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000135967 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000135967 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000135967 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bLANCET : 2015
000135967 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000135967 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000135967 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000135967 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000135967 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000135967 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000135967 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000135967 915__ $$0StatID:(DE-HGF)9940$$2StatID$$aIF >= 40$$bLANCET : 2015
000135967 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lEpidemiologie von Krebserkrankungen$$x0
000135967 980__ $$ajournal
000135967 980__ $$aVDB
000135967 980__ $$aI:(DE-He78)C020-20160331
000135967 980__ $$aUNRESTRICTED